Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NO0K
|
|||
| Former ID |
DIB012629
|
|||
| Drug Name |
RBT-101
|
|||
| Synonyms |
RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec
Click to Show/Hide
|
|||
| Indication | Respiratory tract infection [ICD-11: CA45; ICD-10: J00-J99; ICD-9: 460-519] | Phase 3 | [1] | |
| Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | ||
| Influenza virus infection [ICD-11: 1E30-1E32] | Investigative | [2] | ||
| Company |
Redbiotec AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mammalian target of rapamycin complex 1 (mTORC1) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.